ReviewArthritis care & research2020
Incomplete Systemic Lupus Erythematosus: What Remains After Application of American College of Rheumatology and Systemic Lupus International Collaborating Clinics criteria?
Review in Arthritis care & research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Persistent Antinuclear Antibodies Positivity Predicts Progression to Systemic Lupus Erythematosus in Paediatric Autoimmune Cytopenias: A Retrospective Cohort Study.Mediterranean journal of rheumatology · 2026Article
- Application of the SLERPI scoring system as a classification tool in systemic lupus erythematosus and its performance in early disease recognition.Rheumatology international · 2026Article
- A study of clinical manifestations and associated factors in photosensitive patients with systemic lupus erythematosus.European journal of medical research · 2026Article
- Evaluation of the classification performance and cost-effectiveness of classification criteria in children with systemic lupus erythematosus.Frontiers in pediatrics · 2026Article
- Biomarkers for systemic lupus erythematosus: A scoping review.Immunity, inflammation and disease · 2024Article
- Plasmacytoid Dendritic Cells Are Not Major Producers of Type 1 IFN in Cutaneous Lupus: An In-Depth Immunoprofile of Subacute and Discoid Lupus.The Journal of investigative dermatology · 2024Article
- Article
- Budd-Chiari Syndrome as an Initial Manifestation of Incomplete Systemic Lupus Erythematosus.European journal of case reports in internal medicine · 2024Article
- Genetic susceptibility for autoimmune diseases and white blood cell count.Scientific reports · 2023Article
- Precursors to Systemic Sclerosis and Systemic Lupus Erythematosus: From Undifferentiated Connective Tissue Disease to the Development of Identifiable Connective Tissue Diseases.Frontiers in immunology · 2022Review
- Article
- A Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified Lupus.ACR open rheumatology · 2021Article
- Proportions of B-cell subsets are altered in incomplete systemic lupus erythematosus and correlate with interferon score and IgG levels.Rheumatology (Oxford, England) · 2020Article
Corrections and comments
- Commented on by
- Commented on byReply.2020
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Incomplete systemic lupus (iSLE) is an acknowledged condition of patients with clinical signs of lupus who do not fulfill classification criteria for SLE. Some patients with iSLE have persistent mild disease, but others have serious organ involvement, and up to 55% progress to established SLE. Research on this subject could reveal predictive or diagnostic biomarkers for SLE. Ideally, it would become possible to discern those patients with critical organ involvement or a high risk for progression to SLE. This high-risk group might benefit from early treatment, which would preferably be confirmed in randomized controlled trials. This process would, however, require agreement on a definition of iSLE. The Systemic Lupus International Collaborating Clinics (SLICC) classification criteria was composed in order to diagnose SLE earlier. The present review outlines the clinical characteristics of iSLE after introduction of SLICC criteria and furthermore proposes a definition of iSLE with the aim of discriminating the high-risk group from those with a lower risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.